| Literature DB >> 35647205 |
Xinni Yang1,2,3, Jiyong Tan1,2, Jiqing Shen1, Xin Zhang1, Gaoxiang Huang1, Xiaoxue Su2, Jing Li1,2,4,5.
Abstract
Backgrounds: Skin aging could be regulated by the aberrant expression of microRNAs. In this manuscript, we explain that endothelial cell-derived extracellular vesicles could act as supporters to deliver exogenous miR-326-3p to accelerate skin fibroblasts senescence.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35647205 PMCID: PMC9132672 DOI: 10.1155/2022/3371982
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.493
Figure 1Senescence endothelial cells promoted skin fibroblasts senescence via extracellular vesicles pathway. (a)SA-β-gal staining analyze of D-gal-induced senescence endothelial cells. (b) SA-β-gal staining assay of skin fibroblasts cocultured with endothelial cells treated by PBS, D-gal, and D-gal + GW4869. (c) Hoechst 33258 staining assay of skin fibroblasts cocultured with endothelial cells treated by PBS, D-gal, and D-gal + GW4869. ∗∗p < 0.01 vs. CTRL; #p < 0.05 vs. D-gal;. CTRL: control; D-gal: D-galactose; GW: GW4869.
Figure 2miR-326-3p overexpression in extracellular vesicles of senescence endothelial cells. (a) The expression of miRNAs associated with aging in vascular endothelial cells (VEC). (b) The expression of miRNAs related to senescence in skin fibroblasts (FBS). (c) Electron microscope observation of extracellular vesicles derived from vascular endothelial cells. (d) The miR-326-3p expression in extracellular vesicles (EV) of vascular endothelial cells (VEC). (e) The expression of miR-326-3p in skin fibroblasts after treated with endothelial cell-derived extracellular vesicles. ∗p < 0.05 vs. CTRL; ∗∗p < 0.01 vs. CTRL. ∗∗∗p < 0.001 vs. CTRL. CTRL: control; D-gal: D-galactose; C-EV: control endothelial cell-derived extracellular vesicles; S-EV: senescent endothelial cell-derived extracellular vesicles.
Figure 3miR-326-3p regulated skin fibroblasts biological functions. (a) SA-β-gal staining assay of skin fibroblast cells after treated with miR-326-3p mimic/inhibitor (10×). (b) Apoptosis (Hoechst 33258) staining assay of skin fibroblast cells after treated with miR-326-3p mimic/inhibitor (10×). (c) Ki67 proliferation staining assay of skin fibroblast cells after treated with miR-326-3p mimic/inhibitor (10×). ∗p < 0.05 vs. NC, ∗∗p < 0.01 vs. NC. NC: negative control.
Figure 4TLR4 as a target gene of miR-326-3p. (a) TLR4 mRNA expression in skin fibroblast cells after transfected with miR-326-3p mimic. (b) TLR4 mRNA expression in skin fibroblast cells after transfected with miR-326-3p inhibitor. (c) Predicted binding sites for miR-326-3p target gene TLR4. (d) Double luciferase assay verified the targeted association between TLR4 and miR-326-3p. ∗p < 0.05 vs. NC, ∗∗p < 0.01 vs. NC.
Figure 5TLR4 modulated skin fibroblasts senescence. (a) SA-β-gal staining analysis of skin fibroblasts after transfected with siRNA-TLR4 (10×). (b) SA-β-gal assay of skin fibroblasts after cotransfected with siRNA-TLR4 and miR-326-3p inhibitor (10×). ∗p < 0.05 vs. NC, ∗∗p < 0.01 vs. NC, ∗∗∗p < 0.001 vs. NC. ###p < 0.001 vs. D-gal+miR-326-3p inhibitor.
Figure 6miR-326-3p and TLR4 expression in aging skin tissue. (a) HE staining and dermal thickness analyze of aging mice skin tissue (10×). (b) MASSON staining of aging mice skin tissue (10×). (c) The miR-326-3p expression in aging skin tissue. (d) The TLR4 mRNA expression in aging skin tissue. (e) The expression of TLR4 protein in aging skin tissue. ∗∗p < 0.01 vs. CTRL group. CTRL: control.